| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 16 | 15 | 15 | 19 | 18 |
| Sales Growth | +3.32% | +0.31% | -21.87% | +5.49% | -29.38% |
| Net Income | -1,184 | -1,161 | -1,096 | -1,113 | -1,337 |
| Net Income Growth | -2.01% | -5.91% | +1.52% | +16.75% | -10.22% |
Diagnos Inc. (ADK.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, the United States of America, Mexico, Chile, and others. The company's key revenue is derived from Canada.
Fiscal Year End Date: 03/31